Multiplexed detection of biomarkers using a microfluidic chip integrated with mass-producible micropillar array electrodes.

Quantifying multiple biomarkers with high sensitivity in tiny biological samples is essential to meet the growing demand for point-of-care testing. This paper reports the development of a novel microfluidic device integrated with mass-producible micropillar array electrodes (μAEs) for multiple biomarker detections. The μAE are mass-fabricated by soft lithography and hot embossing technique. Pt–Pd bimetallic nanoclusters (BNC) are modified on the surface of μAEs by constant potential (CP)/multi-potential step (MPS) electrodeposition strategies to improve the electroanalytical performance. The experimental result displays that Pt–Pd BNC/μAEs have good sensitivity enhancement compared with bare planar electrodes and bare μAEs, the enhancement being 56.5 and 9.5 times respectively, from the results of the H 2 O 2 detection. Furthermore, glucose, uric acid and sarcosine were used as model biomarkers to show the biosensing capability with high sensitivity. The linear range and LOD of the glucose, uric acid and sarcosine detection are 0.1 mM–12 mM, 10 μM–800 μM and 2.5 μM–100 μM, 58.5, 3.4 and 0.4 μM, respectively. In particular, biosensing chips show wide linear ranges covering required detection ranges of glucose, uric acid and sarcosine in human serum, indicating the developed device has great potential in self-health management and clinical requirements. [Display omitted] • Mass-producible micropillar array electrodes have been developed. • Pt–Pd nanoclusters were modified to improve performance. • The device performs glucose, uric acid and sarcosine detection. [ABSTRACT FROM AUTHOR]